B. Riley Weighs in on biote's Q1 Earnings (NASDAQ:BTMD)

biote Corp. (NASDAQ:BTMD - Free Report) - Equities researchers at B. Riley issued their Q1 2025 earnings estimates for shares of biote in a report issued on Thursday, March 13th. B. Riley analyst J. Van. Sinderen forecasts that the company will post earnings per share of $0.04 for the quarter. The consensus estimate for biote's current full-year earnings is $0.75 per share. B. Riley also issued estimates for biote's Q2 2025 earnings at $0.05 EPS, FY2025 earnings at $0.29 EPS, FY2026 earnings at $0.42 EPS and FY2027 earnings at $0.71 EPS.

Separately, Craig Hallum cut their price objective on shares of biote from $12.00 to $8.00 and set a "buy" rating on the stock in a research report on Thursday, March 13th.

biote Price Performance

NASDAQ:BTMD remained flat at $4.22 during mid-day trading on Monday. 147,586 shares of the company traded hands, compared to its average volume of 177,831. The stock has a market capitalization of $229.30 million, a PE ratio of 16.33 and a beta of 1.07. The stock's 50 day moving average is $4.85 and its 200 day moving average is $5.51. biote has a 12-month low of $3.04 and a 12-month high of $8.44.

Insiders Place Their Bets

In related news, Director Stephen Mark Cone purchased 38,104 shares of the company's stock in a transaction on Monday, March 17th. The shares were bought at an average cost of $3.88 per share, for a total transaction of $147,843.52. Following the transaction, the director now owns 160,829 shares of the company's stock, valued at $624,016.52. This represents a 31.05 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Guines Llc purchased 750,000 shares of the company's stock in a transaction on Thursday, March 13th. The shares were bought at an average price of $3.22 per share, for a total transaction of $2,415,000.00. Following the completion of the transaction, the insider now directly owns 3,820,938 shares in the company, valued at $12,303,420.36. This represents a 24.42 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 788,204 shares of company stock worth $2,563,218. 13.90% of the stock is owned by corporate insiders.

Remove Ads

Institutional Trading of biote

Several institutional investors and hedge funds have recently added to or reduced their stakes in BTMD. Victory Capital Management Inc. acquired a new stake in biote during the third quarter valued at approximately $106,000. MetLife Investment Management LLC increased its stake in biote by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 16,582 shares of the company's stock valued at $93,000 after buying an additional 9,343 shares during the period. Wasatch Advisors LP increased its stake in biote by 8.4% in the 3rd quarter. Wasatch Advisors LP now owns 1,392,809 shares of the company's stock valued at $7,772,000 after buying an additional 107,792 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in biote by 24.9% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 272,377 shares of the company's stock valued at $1,520,000 after buying an additional 54,302 shares during the period. Finally, Quarry LP acquired a new position in shares of biote during the 3rd quarter worth $104,000. 21.68% of the stock is owned by institutional investors and hedge funds.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.